Pharmacological inhibition of the ataxia telangiectasia and Rad3-similar protein serine/threonine kinase (ATR; generally known as FRAP-associated protein (FRP1)) has emerged like a promising strategy for most cancers cure that exploits artificial lethal interactions with proteins involved with DNA injury fix, overcomes resistance to other therapies